BUZZ-Microcap Kazia shares soar 40% after positive drug update on single-patient treatment
Shares of Kazia Therapeutics surged 34% to $7.79 after reporting positive early-stage results in a patient with stage IV triple-negative breast cancer using a combination of Kazia's drug, paxalisib, and Merck's Keytruda. The treatment achieved an initial immune-complete response. Kazia has 1.67 million shares outstanding and a market value of $9.6 million. The session high was $8.54, the highest since September 11. Merck shares remained unchanged at $96.52.
Shares in microcap Kazia Therapeutics (KZIA.O) jump 34% to $7.79 on Wednesday after it reported positive early stage results in one patient with stage IV triple-negative breast cancer treated under an FDA-authorized single-patient protocol combining Kazia’s drug, paxalisib, with pembrolizumab (Keytruda®), from Merck & Co (MRK.N) Kazia said that, along with chemotherapy, the treatment of the patient with a highly aggressive metastatic cancer subtype achieved “an initial immune-complete response (iCR)” as per iRECIST criteria
The Sydney-based co’s latest results follow its October 2 report of an 86% reduction in tumor burden after three weeks of treatment in the same patient
KZIA says the patient remains on therapy, under active clinical monitoring and that a follow-up scan will be conducted to confirm the initial scan
KZIA has just 1.67 million shares outstanding and a market value of $9.6 million Session high of $8.54 was its highest level since September 11, when it also announced positive results. Shares still down slightly YTD after closing out 2024 at $8.85
MRK shares were virtually unchanged at $96.52
